Built by Experts in Access & Delivery
Our Founders & Vision
MAPRIUM was founded by industry leaders with deep experience in Global Managed Access, Clinical Research Operations and compliant technology delivery
Our Mission
We understand the realities of running access programs — the regulatory complexity, operational burden and ethical responsibility involved.
Our mission is to modernize Managed Access by providing a robust, scalable digital platform that supports patients, healthcare professionals and pharmaceutical organizations alike.
Vision
The Maprium platform will transform how MAPs are designed, governed
and delivered.
By supporting compliant, auditable, and scalable access programs - whilst
improving transparency and decision-making for sponsors and partners alike.
The Vision
Maprium’s vision is for a world in which ever-increasing patient demand for access to unlicensed medicines can be managed efficiently, rapidly and safely.
Recognized as a global expert in Managed Access Programs (MAP), Romina
Oxborough founded Maprium to address the difficulties caused by
long-standing inefficiencies, risk and fragmentation in MAP execution.
Maprium enables pharmaceutical companies to manage multiple MAPs, across
different geographies and providers, in one single solution - improving
consistency, efficiency and safety.
Romina Oxborough
Founder & CEO
Romina is one of the leading experts in Managed Access Programs (MAPs) and early access strategy with more than 20 years’ experience spanning scientific research, clinical operations, pharmaceutical access and healthcare technology.
PhD and MBA-qualified, she began her career in scientific research, co-authoring to more than 20 scientific publications before moving into global pharmaceutical access, strategy, and operational leadership with roles at IQVIA, IXICO, IDIS and Clinigen.
Recognised for her expertise in the operationalisation and governance of global access programs, Romina has helped pharmaceutical companies navigate the complexities of providing patients with access to innovative medicines worldwide.
As Founder and CEO, Romina is focused on transforming how Managed Access Programs are delivered through technology-enabled oversight, governance, and operational excellence - helping pharmaceutical companies achieve greater visibility, coordination, compliance, and scalability across increasingly complex global access landscapes.
John Ryan
Chief Technology Officer
John is a technology executive with more than 20 years’ experience building and scaling software platforms in clinical research, healthcare, and medical education.
As CTO of Longboat Clinical, he helped grow the company into a leading clinical trial technology provider prior to its acquisition by Advarra, where he later served as SVP of Sponsor Technology and Chief Scientist.
John has also founded and scaled multiple healthcare technology and eLearning platforms used internationally by healthcare professionals, universities, and health systems. Originally a radiographer, he holds a PhD in Computer Science and has lectured internationally at institutions including Harvard Medical School, the University of Sydney, and Trinity College Dublin.
At Maprium, he leads technology strategy, platform architecture, and AI innovation for next-generation managed access solutions.
Our Investors and Advisors
Maprium is supported by a strong group of investors and advisors who share our vision to help pharmaceutical companies to enable patients to access the medicines they need in a timely, safe and compliant manner.
Natalie Douglas
Natalie is a multi-award-winning executive, board advisor, and investor with more than 25 years of experience Leading private equity and venture-backed healthcare, pharma services, and MedTech organisations.
Widely recognised as a pioneer in global managed access programmes, she built and led IDIS (now Clinigen), transforming it into the leading international provider of early and expanded access programmes and helping shape what is now considered the industry standard for global managed access.
Natalie has continued to work closely with innovative healthcare and technology businesses as a board member, investor, and strategic advisor. Known for combining commercial insight with operational excellence, Natalie has built a reputation for scaling high-growth organisations, navigating complex global markets, and driving innovation in healthcare delivery.
Gerard Ryan
Gerard is a qualified Pharmacist and Chartered Director (IoD) with a distinguished track record as an entrepreneur, investor and business leader.
Over the course of his career, he has successfully founded, scaled and exited four companies through trade sales, primarily within the healthcare, MedTech and life sciences sectors.
In addition to his entrepreneurial achievements, Gerard is an active angel investor with investments in more than 38 companies, supporting innovative businesses across MedTech, healthcare and life sciences.
He is widely recognised for combining deep sector expertise with strategic leadership and a strong focus on commercialising novel products and unique business models.
Ken O’Connell
Ken is an experienced finance and business leader with a strong track record in the healthcare, pharmaceutical, medical device, and technology sectors.
He currently serves as Finance Director of RGH Capital, where he supports investments in start-ups across technology, medical, healthcare, and biotech industries. Previously, he was Chief Financial Officer of Firecrest Clinical, contributing to the company’s growth and its successful acquisition by ICON plc.
Ken was also co-founder and Chief Executive Officer of Longboat Clinical, where he led all aspects of the business from inception through to its successful acquisition by Advarra.
In addition to his executive leadership roles, he is an active investor and board member in a number of technology companies operating within the pharmaceutical and medical device sectors.
Mark Good
Mark is Head of Private Equity at Abbey International Finance, where he is responsible for sourcing, structuring and managing investments across Ireland and the UK.
His work spans strategy, corporate finance, portfolio management and business growth, with a focus on supporting management teams.
Mark works with investee companies and investment partners on funding, strategy and value creation initiatives. He also serves in board-level roles across a number of Abbey’s portfolio companies. Mark holds an engineering degree and an MBA, which support a practical and analytical approach to his investment work.
Niall McKeon
Niall is a Chartered Accountant with over 30 years’ experience, including over two decades in C-suite and senior leadership roles.
He has extensive expertise across finance, private equity, investment strategy and business growth, with a strong track record of supporting and scaling businesses across multiple industries and international markets.
Niall also serves as a board member and non-executive director for a number of investee companies. Since 2009, he has been Chief Financial Officer of Abbey International Finance, where he plays a key role in driving the firm’s investment and growth strategy.
Tom Howard
Tom is an established entrepreneur with multiple investments in various companies in the pharmaceutical and healthcare sectors.
Tom was a director and investor in Longboat Clinical before it was acquired by Advarra in 2020. Tom was also a director and investor in Firecrest Clinical until its sale in 2011. Tom currently holds a number of non-executive directorships in the healthcare sector.
